An Overview of the Current Clinical Landscape of Antibody Drug Conjugates
Wednesday, November 23rd, 2016 11:00 AM – 12:00 PM EST
Many of the early ADCs have failed to progress through clinical testing. As such, there are currently 2 licenced ADCs in the US, brentuximab vedotin (Adcetris) and ado-trastuzumab emtansine (Kadcyla). The rates of attrition of ADCs in the clinic seem particularly high, with about 1/3 ADCs failing to progress past phase I. However, a huge amount of preclinical work has led to the generation of novel ADCs, which are more stable, have more specific targeting and have improved payloads. This evolution of ADCs in the laboratory has provided a robust preclinical pipeline of drug candidates, which have started entering clinical trials. In 2015 there were 17 novel ADCs entering clinical testing for the first time, with a similar trend identified in 2016. Moreover there has been significant movement to phase II and III trials in the last year, suggesting that better designed ADCS may progress through clinical trials more rapidly than traditional drugs.
In this webinar I will present the current clinical landscape of ADCs, focussing on active compounds. I will highlight key movements in the pipeline during the last 12 months and will discuss trends identified in the evolving landscape.
Heather Donaghy, Research Analyst for Beacon, Hanson Wade
To register for this webinar, please click here.
For further assistance and information, please don’t hesitate to email email@example.com.